Kornitzer Capital Management Inc. KS Sells 15,818 Shares of Progyny, Inc. $PGNY

Kornitzer Capital Management Inc. KS reduced its position in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 22.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,227 shares of the company’s stock after selling 15,818 shares during the period. Kornitzer Capital Management Inc. KS owned 0.07% of Progyny worth $1,416,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Progyny in the second quarter worth $334,426,000. Bank of America Corp DE grew its stake in shares of Progyny by 75.3% in the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after buying an additional 511,609 shares in the last quarter. William Blair Investment Management LLC bought a new stake in shares of Progyny in the 2nd quarter worth about $16,807,000. Principal Financial Group Inc. increased its holdings in shares of Progyny by 16.4% in the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after buying an additional 78,198 shares during the last quarter. Finally, Danske Bank A S bought a new stake in shares of Progyny in the 2nd quarter worth about $15,243,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity

In related news, CEO Peter Anevski sold 161,308 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $35.73, for a total transaction of $5,763,534.84. Following the completion of the transaction, the chief executive officer owned 762,468 shares in the company, valued at $27,242,981.64. The trade was a 17.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman David Schlanger sold 161,208 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $35.73, for a total value of $5,759,961.84. Following the transaction, the chairman owned 238,462 shares of the company’s stock, valued at approximately $8,520,247.26. The trade was a 40.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 357,276 shares of company stock worth $12,602,622 in the last three months. Corporate insiders own 9.90% of the company’s stock.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

  • Positive Sentiment: Wall Street Zen upgraded Progyny to “Strong Buy,” providing a bullish signal for the stock. Article: Progyny Upgraded to Strong-Buy at Wall Street Zen
  • Neutral Sentiment: JPMorgan raised its price target to $35 from $30 but kept a “Neutral” rating, indicating a higher valuation expectation without an outright bullish call. JPMorgan ratings
  • Negative Sentiment: CEO Peter Anevski and Chairman David Schlanger each reported selling about 161,000 shares on Nov. 9, in addition to smaller sales reported for Nov. 5. The sizable sales could raise investor concerns about insider confidence, although the transactions were conducted under pre-arranged Rule 10b5-1 plans. CEO SEC filing Chairman SEC filing

Wall Street Analyst Weigh In

A number of brokerages recently commented on PGNY. Citizens Jmp increased their price target on shares of Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a report on Thursday, November 5th. Canaccord Genuity Group set a $35.00 price objective on Progyny in a research note on Friday, August 7th. Barclays dropped their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. Wells Fargo & Company boosted their target price on Progyny from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, KeyCorp boosted their target price on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Eleven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Check Out Our Latest Stock Analysis on Progyny

Progyny Trading Up 3.2%

Shares of NASDAQ:PGNY opened at $35.95 on Tuesday. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 2.08 and a beta of 0.97. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $36.00. The firm’s 50-day moving average is $27.65 and its 200 day moving average is $24.64.

Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.23%. The company had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same period in the prior year, the company posted $0.15 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, equities analysts forecast that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Progyny Company Profile

(Free Report)

Progyny, Inc provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment.

The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Founded in 2008, Progyny serves employer clients and their workforces in the United States.

Featured Articles

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.